In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

From antibiotic resistance to emerging viral threats, the global demand for new medicines is intensifying, yet traditional drug discovery pipelines remain slow and expensive. A new scientific review ...

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. But the deal is a little different compared to many recent deals ...

Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...

Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug molecules ...

AlphaFold, a transformative AI-driven tool developed by DeepMind, has revolutionized the field of structural biology by accurately predicting protein structures. This breakthrough holds significant ...

Andrew Pierce is the senior vice president of discovery and development at a company that claims to be “first end-to-end AI biotech,” but he admits he doesn’t know the first thing about artificial ...

New FDA guidelines for personalized genomic drug development are a step forward in advancing new therapies for ultrarare diseases, but industry leaders need further clarification.

There is a better way. The U.S. could spend its health care dollars on universal insurance, vaccines, and screening.

It’s always a high-stakes gamble in the pharmaceutical industry to develop a new drug. The process typically takes 10 to 15 years and requires extensive testing, regulatory approval, and clinical ...

The research by Turkish scientists who developed the 'invisible keys' technology in drug design offers a critical opportunity ...